In oncology, “immunotherapy” is a broad term encompassing multiple means of utilizing the patient’s immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.

中文翻译：

---

成人免疫肿瘤学：利用过去的失败经验来指导未来。

在肿瘤学中，“免疫疗法”是一个广义术语，涵盖了多种利用患者免疫系统对抗恶性肿瘤的手段。其中突出的是免疫检查点抑制剂，包括嵌合抗原受体T细胞疗法在内的细胞疗法，疫苗和溶瘤病毒。胶质母细胞瘤（GBM）的免疫疗法在早期试验中取得了好坏参半的结果。在这种情况下，临床，研究和思想领袖以及患者倡导者在2019年首届年度缓解峰会上讨论了免疫肿瘤学用于治疗GBM的过去，现在和未来。目标是利用当前知识（已发表和未发表）来确定治疗失败的可能原因，以及将免疫疗法作为GBM患者治疗方式的最佳策略。讨论集中于过去的失败，